Insight

OncoDaily

News Feed Opinion Career Insight Dialogues Blog Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Insight

Photo of NEJM from tukuz.com

May 28, 2024, 07:48

Full results and Plain Language Summary for CheckMate 77T trial – NEJM

NEJM shared on X/Twitter:

“In the CheckMate 77T trial, researchers assessed whether adding adjuvant nivolumab to neoadjuvant nivolumab plus chemotherapy would improve outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Full results and Plain Language Summary.”

Perioperative Nivolumab in Resectable Lung Cancer A PLAIN LANGUAGE SUMMARY Top Figure: Illustration of treatment options during the Neoadjuvant and Adjuvant Periods. Bottom Figure: Graph of the Percentage of Patients with Event-free Survival

Source: NEJM/X

adjuvant nivolumab cancer CheckMate 77T trial NEJM neoadjuvant nivolumab OncoDaily Oncology resectable NSCLC

Jul 5, 2024, 17:50

First-of-its-kind PhD program in cancer engineering - MSKCC

Jul 5, 2024, 17:27

Julie Ross shares the story of her career journey with OncoDaily - Advanced Clinical

Jul 5, 2024, 16:59

Pat Price: As we approach the general election, cancer must be a top priority for our new Government

Jul 5, 2024, 16:32

July edition of the IAPC's newsletter

Jul 5, 2024, 16:31

Fumiko Ladd Chino: I strongly support Dr Neha Vapiwala for President at ASTRO

Jul 5, 2024, 16:30

CAR NK cells with CD28 costimulation improved cell persistence and antitumor activity

Jul 5, 2024, 16:21

Latest episodes from the Precision Medicine podcast

Jul 5, 2024, 16:12

Sunscreen Is Your Best Friend This Summer - Sylvester Cancer Experts

Jul 5, 2024, 15:53

Gevorg Tamamyan: Waiting too see promising bot/bal results from our lung cancer trial

Jul 5, 2024, 15:41

Development of an EORTC QoL module for patients with advanced melanoma

Jul 5, 2024, 15:32

Gemma Peters: The new government has an opportunity to fix our broken cancer care system

Jul 5, 2024, 15:03

Andrea Apolo: Phase 1 study of Cabozantinib, Nivolumab, and Ipilimumab for genitourinary tumours